EU/3/18/2118

About

On 14 December 2018, orphan designation (EU/3/18/2118) was granted by the European Commission to Eiger Biopharmaceuticals Europe Limited, United Kingdom, for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome.

The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in August 2019.

Key facts

Active substance
Lonafarnib
Disease / condition
Treatment of Hutchinson-Gilford progeria
Date of first decision
14/12/2018
Outcome
Positive
EU designation number
EU/3/18/2118

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Eigerbio Europe Limited
1 Castlewood Avenue
Rathmines
Dublin 6, D06 H685
Ireland
Tel. +1 650 272 6138
E-mail: info@eigerbio.com 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating